Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Preclinical Safety Evaluation and First-in-Human Translational Study of [177Lu]Lu-TEFAPI-06: A Novel Albumin-Binding FAPI Radiopharmaceutical for Theranostics

NCT07299253 is registered in ClinicalTrials.gov with Lanzhou University Second Hospital as lead sponsor.

NCT NCT07299253
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07299253 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Preclinical Safety Evaluation and First-in-Human Translational Study of [177Lu]Lu-TEFAPI-06: A Novel Albumin-Binding FAPI Radiopharmaceutical for Theranostics
Lead sponsor
Lanzhou University Second Hospital
Phase
Phase 1
Overall status
Completed
Start date
August 16, 2023
Completion date
August 16, 2025
Enrollment
5 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic solid tumors (any localization)